logo
TOXINS2026:ClinicalUpdatesonGalderma’sLeadingNeuromodulatorPortfolioFurtherReinforceItsLeadershipinInjectableAesthetics
===2026/1/14 14:24:31===
353.

Relfydess®. EU Summary of Product Characteristics.

Sundberg AL and Stahl U. Relabotulinum toxin - a novel, high purity BoNT-A1 in liquid formulation. Presented at TOXINS; January 16-17, 2021; virtual meeting.

Do M, et al. Purification process of a complex-free highly purified botulinum neurotoxin type A1 (BoNT-A1) - relabotulinumtoxinA. Presented at TOXINS; July 27-30, 2022; Louisiana, United States.








Contacts


Christian Marcoux, M.Sc.
Chief Communications Officer
christian.marcoux@galderma.com
+41 76 315 26 50

Richard Harbinson
Corporate Communications Director
richard.harbinson@galderma.com
+41 76 210 60 62

Céline Buguet
Franchises and R&D Communications Director
celine.buguet@galderma.com
+41 76 249 90 87

Emil Ivanov
Head of Strategy, Investor Relations, and ESG
emil.ivanov@galderma.com
+41 21 642 78 12


=*=*=*=*=*=
当前为第9/10页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页